Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer
Authorsde, Ruysscher D
AffiliationMaastricht University Medical Center, Department of Radiation Oncology (Maastro), GROW School for Oncology and Developmental Biology, Maastricht, The Netherlands
MetadataShow full item record
AbstractConcurrent chemotherapy and radiotherapy (CCRT) followed by durvalumab immune therapy in appropriate patients is considered to be the standard of care in most fit stage III non-small-cell lung cancer (NSCLC) patients. However, CCRT is a toxic treatment that affects all organ systems and may cause acute and permanent side effects, some of which may be lethal. Supportive care is therefore of utmost importance in this clinical setting. A group of experts from the European Society for Therapeutic Radiology and Oncology (ESTRO) and the European Society of Medical Oncology (ESMO) identified the following items of importance for further improvement of supportive care: smoking cessation; nutrition before and during CCRT (including treatment and prevention of anorexia); physical exercise before and during CCRT; prevention and treatment of acute esophagitis and dysphagia; treatment of cough and dyspnea; treatment of skin reactions; treatment of fatigue; prophylaxis of nausea and emesis; prevention, diagnosis, and treatment of cardiac disease and damage; and optimization of radiotherapy techniques and chemotherapy adjustments to reduce toxicity in the era of immune therapy. The resulting recommendations are summarized in this manuscript and knowledge gaps identified, in which future investments are needed to improve supportive care and hence quality of life and survival for our stage III NSCLC patients.
CitationDe Ruysscher D, Faivre-Finn C, Nackaerts K, Jordan K, Arends J, Douillard JY, et al. Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer. Ann Oncol. 2020;31(1):41-9.
JournalAnnals of Oncology
- Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): a European survey conducted by the European Society for Medical Oncology (ESMO) young oncologists committee.
- Authors: Califano R, Karamouzis MV, Banerjee S, de Azambuja E, Guarneri V, Hutka M, Jordan K, Kamposioras K, Martinelli E, Corral J, Postel-Vinay S, Preusser M, Porcu L, Torri V
- Issue date: 2014 Jul
- [Concurrent chemoradiotherapy followed by consolidation chemotherapy and sequential chemoradiotherapy for stage III non-small cell lung cancer: comparison in 93 patients].
- Authors: Sun WZ, Song LP, Zhang YB, Ai T, Lu JL, Ren J, Gao Y
- Issue date: 2012 Mar
- Implementation of durvalumab maintenance treatment after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC)-a German radiation oncology survey.
- Authors: Käsmann L, Eze C, Taugner J, Roengvoraphoj O, Belka C, Manapov F
- Issue date: 2020 Apr
- Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
- Authors: Logan DM, Lochrin CA, Darling G, Eady A, Newman TE, Evans WK
- Issue date: 1997 Dec